Genentech’s cancer immunotherapy Tecentriq shrank tumours in people with previously untreated advanced bladder cancer

Genentech has announced that in a Phase II study, IMvigor 210, Tecentriq (atezolizumab) shrank tumours (objective response rate, ORR) in 24% of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received a prior treatment (first-line) and who were ineligible for cisplatin-based chemotherapy. Of those people who responded, 75% continued to respond to treatment and the median duration of response (DOR) had not been reached at the time of analysis. Seven percent of all people in the study achieved a complete response (CR). The median overall survival (OS) was 14.8 months. The safety profile of Tecentriq was consistent with that observed in an earlier analysis of the study, as well as in other studies of Tecentriq as a monotherapy. Full results will be presented in an oral session at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) and highlighted as part of ASCO’s official press program.